The CEO addicted to challenge

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Angelo Gatto, CEO at Chanelle Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Angelo, covering:

• Why he chose to follow a big pharma divestment into the CDMO industry. The tricky transition from big pharma technical to commercial CDMO BD when he had the view of "I don't like sales people"!


• How commercial trust is developed through preparation, character and competences


• Why he couldn't resist the 'made for him' CEO role at Chanelle Pharma


• Making key strategic decisions to that make the business very attractive to a range of future buyers.


• The humanisation of animal care driving the pipeline and development of new products for small and large animals

Angelo brings over 25 years of international experience in pharmaceuticals, in a career spanning animal health, human health and CDMO. He has held operations, commercial and management roles at Johnson & Johnson, AlfaSigma, Pfizer, Aenova Group, Adragos Pharma. 

Since July 2024 is the CEO of Chanelle Pharma, Before joining Chanelle he also created a boutique advisory firm that has helped companies in last years to succeed in M&A deals and value creation, mostly in the CDMO space.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.